Value-Based Purchasing and Comparative Effectiveness Research

Share this article:
Value-Based Purchasing and Comparative Effectiveness Research
Value-Based Purchasing and Comparative Effectiveness Research
Value-Based Purchasing and Comparative Effectiveness: Why the Pharmaceutical, Biotechnology, and Medical-Surgical Device Industries Should Embrace the Coming Market Evolution

For years, health economics has assisted healthcare stakeholders in making informed evaluations of treatment alternatives. Now, the advent of value-based purchasing (VBP) and comparative effectiveness research (CER) are leading to new methods for identifying products with the highest "value"—those that ideally deliver both overall cost reductions and improved patient health. These trends will increasingly impact the way healthcare products are marketed and sold.

This paper examines the march to VBP and CER evaluations, and makes specific recommendations to manufacturers and brand teams regarding how combining clinical and economic data is essential to the successful marketing of drugs and devices.

Please click here to download this white paper.

About MarCom Group International, Inc.:

MarCom Group International works with US and global pharmaceutical, medical-surgical, and biotechnology companies to provide medical marketing communications, health economics, and physician education services. MarCom's health economics team combines expert research, strategic analytics, and scientific communications for world-class results.

Click here for more information about MarCom Group International, Inc.





How to download the MarCom White Paper:

If you don't have a username and password to mmm-online.com,
  • Click "register here" on the MarCom White Paper download page
  • Enter in your contact information
  • An email will be sent to your email address with a link to confirm your registration
  • Click on the link in your email to sign in your username and new password
  • Download the MarCom White Paper



Share this article:

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.